Pieris Publication

Coby M. M. Laarakkers, Erwin T. Wiegerinck, Siem Klaver, Maria Kolodziejczyk, Hendrik Gille, Andreas M. Hohlbaum, Harold Tjalsma, Dorine W. Swinkels (2013) Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. (2013) A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther. Sep 3.

Martz L. (2009) Designer Lipocalins. SciBX 2(28) 8-9. Kim, H.J., Eichinger, A., Skerra A. (2009) High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc. 131(10):3565-76.

Skerra, A. (2008) Alternative binding proteins: Anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 275(11):2677-83

Breustedt, D.A., Schonfeld, D.L., Skerra, A. (2006) Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta. 1764(2), 161-173.

Nasreen, A., Vogt, M., Kim, H.J., Eichinger, A., Skerra, A. (2006) Solubility engineering and crystallization of human apolipoprotein D. Protein Sci. 15(1), 190-199.

Vopel, S., Muhlbach, H., Skerra, A. (2005) Rational engineering of a fluorescein-binding anticalin for improved ligand affinity. Biol Chem. 386(11), 1097-1104.

Schlehuber, S. & Skerra, A. (2005) Anticalins in Drug Development. BioDrugs, 19(5), 279-288.

Schlehuber, S. & Skerra, A. (2005) Anticalins as an alternative to antibody technology. Expert Opin. Biol. Ther. 5(11), 1453-1462.

Schlehuber, S. & Skerra, A. (2005) Lipocalins in drug discovery: from natural ligand-binding proteins to ‘anticalins’. Drug Discov. Today 10, 23-33.